

Summary of Product Characteristics

1. Name of the medicinal product

Orchazid 0.25 mg/ml, eye drops, solution.

2. Qualitative and quantitative composition

One ml contains 0.345 mg ketotifenfumarate corresponding to 0.25 mg ketotifen.

Each drop contains 8.5 microgram ketotifenfumarate.

Excipients: Benzalkonium chloride (0.1 mg/ml).

For a full list of excipients, see section 6.1.

3. Pharmaceutical form

Eye drops, solution.

Clear, colorless solution

4. Clinical particulars

4.1 Therapeutic indications

Symptomatic treatment of seasonal allergic conjunctivitis

4.2 Posology and method of administration

Adults, elderly and children (age 3 and older): one drop of **Orchazid** into the conjunctival sac twice a day.

The contents and dispenser remain sterile until the original closure is broken.

To avoid contamination do not touch any surface with the dropper tip.

Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

4.3 Contraindications

Hypersensitivity to ketotifen or to any of the excipients.

4.4 Special warnings and precautions for use

The formulation of **Orchazid** eye drops contains benzalkonium chloride as a preservative, which may be deposited in soft contact lenses; therefore **Orchazid** eye drops should not be instilled while the patient is

wearing these lenses. The lenses should be removed before application of the drops and not reinserted earlier than 15 minutes after use.

All eye drops preserved with benzalkonium chloride may possibly discolor soft contact lenses. Benzalkonium chloride may cause eye irritation.

4.5 Interaction with other medicinal products and other forms of interaction

If **Orchazid** is used concomitantly with other eye medications there must be an interval of at least 5 minutes between the two medications.

The use of oral dosage forms of ketotifen may potentiate the effect of CNS depressants, antihistamines and alcohol. Although this has not been observed with **Orchazid** eye drops, the possibility of such effects cannot be excluded.

4.6 Pregnancy and lactation

Pregnancy

There are no adequate data from the use of ketotifen eye drops in pregnant women.

Animal studies using maternally toxic oral doses showed increased pre- and postnatal mortality, but no teratogenicity. Systemic levels after ocular administration are much lower than after oral use. Caution should be exercised when prescribing to pregnant women.

Lactation

Although animal data following oral administration show excretion into breast milk, topical administration to human is unlikely to produce detectable quantities in breast milk. **Orchazid** eye drops can be used during lactation.

Fertility

There are no data available on the effect of **Orchazid** on fertility in humans.

4.7 Effects on ability to drive and use machines

Any patient who experiences blurred vision or somnolence should not drive or operate machines.

4.8 Undesirable effects

Adverse reactions are ranked under heading of frequency, using the following convention: Very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$), not known (cannot be estimated from the available data).

Immune system disorders

Uncommon: Hypersensitivity

Nervous system disorders

Uncommon: Headache

Eye disorders

Common: Eye irritation, eye pain, punctate keratitis, and punctate corneal epithelial erosion.

Uncommon: Vision blurred (during instillation), dry eye, eyelid disorder, conjunctivitis, photophobia, conjunctival hemorrhage.

Gastrointestinal disorders

Uncommon: Dry mouth

Skin and subcutaneous tissue disorders

Uncommon: Rash, eczema, urticaria

General disorders and administration site conditions

Uncommon: Somnolence

Adverse drug reactions from post-marketing experience (Frequency not known):

The following post marketing events have also been observed: hypersensitivity reactions including local allergic reaction (mostly contact dermatitis, eye swelling, eyelid pruritis and oedema), systemic allergic reactions including facial swelling/oedema (in some cases associated with contact dermatitis) and exacerbation of pre-existing allergic conditions such as asthma and eczema.

Reporting of suspected adverse reactions

The reporting of suspected adverse reactions after authorization of the drug is important. It knows continuous monitoring of the benefit/risk ratio of the drug.

Report any suspected adverse reactions EPVC Email: PV.followup@edaegypt.gov.eg

4.9 Overdose

No case of overdose has been reported.

Oral ingestion of the contents of a 5 ml bottle would be equivalent to 1.25 mg of ketotifen which is 60% of a recommended oral daily dose for a 3 year old child. Clinical results have shown no serious signs or symptoms after oral ingestion of up to 20 mg of ketotifen.

5. Pharmacological properties

5.1 Pharmacodynamics properties

Pharmacotherapeutic group: Ophthalmological, other anti-allergies

ATC code: S01GX08

Ketotifen is a histamine H1-receptor antagonist. In vivo animal studies and in vitro studies suggest the additional activities of mast cell stabilization and inhibition of infiltration, activation and degranulation of eosinophils.

5.2 Pharmacokinetic properties

In a pharmacokinetic study conducted in 18 healthy volunteers with **Orchazid** eye drops, plasma levels of ketotifen after repeated ocular administration for 14 days were in most cases below the limit of quantitation (20 pg/ml).

After oral administration, ketotifen is eliminated biphasically with an initial half-life of 3 to 5 hours and a terminal half-life of 21 hours. About 1% of the substance is excreted unchanged in the urine within 48 hours and 60 to 70% as metabolites. The main metabolite is the practically inactive ketotifen-N-glucuronide.

5.3 Preclinical safety data

Preclinical data reveal no special hazard which is considered relevant in connection with use of **Orchazid** eye drops in humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.

6. Pharmaceutical particulars

6.1 List of excipients

Benzalkonium chloride

Glycerol

1 M Sodium hydroxide

Water for injections

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

In unopened bottle: 2 years.

After opening: 30 days.

6.4 Special precautions for storage

Do not store above 30 °C.

6.5 Nature and contents of container

Carton box containing white (LDPE) plastic bottle with white plastic (LDPE) self-dropper containing 5 ml solution covered with white (PP) plastic cover and inner leaflet.

6.6 Special precautions for disposal and other handling

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Orchidia pharmaceutical industries
El-obour city, Industrial zone, Area 14, 15, Block no. 12011 , Cairo , Egypt
Telephone: (202) 4665 14 80
Fax: (202) 4665 14 75
E-mail: info@orchidiapharma.com
www.orchidiapharma.com

8. MARKETING AUTHORISATION NUMBER(S)

05779/6493/NMR/2018

9. Date of first authorisation/renewal of the authorisation

10/201410/2023

10. DATE OF REVISION OF THE TEXT

08/2023